The study of mechanobiology is now widespread. The impact of cell and tissue mechanics on cellular responses is well-appreciated. However, knowledge of the impact of cell and tissue mechanics on pharmacological responsiveness, and its application to drug screening and mechanistic investigations have been very limited in scope. We emphasise the need for a heightened awareness of the important bidirectional influence of drugs and biomechanics in all living systems. We propose that the term "Mechanopharmacology" be used to describe a new inter-disciplinary area that uses in vitro systems that are biomechanically appropriate to the relevant (patho)physiology, to identify new drugs and drug targets. Mechanopharmacology as an inter-discipline can be applied more broadly to the understanding of biomechanical influences on drug responses. The study of mechanobiology is now widespread. The impact of cell and tissue 54 mechanics on cellular responses is well-appreciated. However, knowledge of the 55 impact of cell and tissue mechanics on pharmacological responsiveness, and its 56 application to drug screening and mechanistic investigations have been very 57 limited in scope. We emphasise the need for a heightened awareness of the 58 important bidirectional influence of drugs and biomechanics in all living 59 systems. We propose that the term "mechanopharmacology" be applied to 60 approaches that use in vitro systems that are biomechanically appropriate to the 61 relevant (patho)physiology, to identify new drugs and drug targets. This article 62 describes models and techniques that are being developed to transform drug 63 screening and evaluation ranging from a 2 dimensional environment to the 64 dynamic 3 dimensional environment of the target expressed in the disease of 65 interest. 66 shown to subserve the recruitment of the actin cytoskeleton to focal adhesions in 108 the leading edge of migrating cells [5, 6]. 109 110 The impact of biomechanics on drug actions is rarely addressed, despite being 111 highlighted as an important consideration repeatedly in the literature, for 112 example, [7, 8] Persistent 278 relaxation of the airways by long-acting β2-adrenoceptor agonists would be 279 expected to offset these stimuli to remodeling, but this has yet to be convincingly 280 demonstrated.
test this proposition against comparator preclinical efficacy testing in relevant 99 animal models and in 2 dimensional culture on rigid plastic substrate. 100
101
The impact of biomechanics on cell function has been systematically explored, 102 leading to a broad appreciation of mechano-sensitive processes, with the 103 principal mechanosensors being selected ion channels [2, 3] and less commonly 104 the integrins [4] . Mechanotransduction involves force transmission through 105 bound proteins resulting in conformational changes that entrain functional 106 impacts. For example, conformational changes in vinculin and talin have been 107
shown to subserve the recruitment of the actin cytoskeleton to focal adhesions in 108 the leading edge of migrating cells [5, 6] . 109
110
The impact of biomechanics on drug actions is rarely addressed, despite being 111 highlighted as an important consideration repeatedly in the literature, for 112 example, [7, 8] . Recent advances proposed by Donald Ingber and colleagues 113 using "organ-on-a-chip" microfluidics technology involving cell cultures being 114 subjected to cyclical strains (breathing/cardiac cycle/peritoneal 115 peristalsis/renal fluidic shear), raise the prospect of more systematic and 116 relevant drug discovery paradigms using human cell cultures [9] [10]. Similarly, 117 recent advances in cell mechanics have highlighted the suitability of mechanical 118 endpoints as phenotypic targets in high-throughput screening [11] . In this 119 article, we develop selected examples of biomechanical impacts on cell function 120 and drug responsiveness and discuss refined, biomechanically appropriate 121 bioassays, emphasizing those suitable for scaling to medium to high throughput. 122
We exemplify below the selected impacts of different aspects of the 123 biomechanical environment (Box 1.) 124 125 126
Shear forces 127
The effects of shear are extensively explored in the cardiovascular system [7] , 128 but there are other organs where fluid and gas flows create shear forces that 129 impact on cell and tissue function. Shear represents the frictional force exerted 130 by flow of gas or liquid over the affected surface and is quantitated in terms of 131 force (Dyne) per unit area (see Box 1). 132
One of the most instructive exemplars of the interaction between drug action 133 and shear stress is provided by the discovery of excess cardiovascular mortality 134 associated with the use of cyclo-oxygenase-2 (COX-2) selective inhibitors 135 (coxibs). The cyclo-oxygenase enzymes comprise COX-1, which is ubiquitously 136 expressed at significant levels and produces precursor for the formation of 137 prostaglandin E2, prostacyclin (PGI2) and thromboxane A2, to achieve 138 cytoprotective, anti-atherogenic, and hemostatic physiological functions, 139 respectively. COX-2 was discovered in tumour cells and has been shown to be 140 strongly induced by certain cytokines, growth factors and pathogen-associated 141 molecular pattern receptors of the mammalian innate host defence system. 142
The basis of the anticipated safety profile of selective cyclo-oxygenase-2 (COX-2) 143 inhibitors was in part dependent on a misapprehension of the dependence of 144 vascular endothelial PGI2 production on COX-1 activity. The anti-thrombotic 145 actions of PGI2 were well-established a decade before the 1990 discovery of COX-146 2. The mechanisms of anti-thrombotic actions of low dose aspirin were known to 147 involve preserved endothelial PGI2 production and diminished production by 148 platelets of the platelet-activating vasoconstrictor, thromboxane A2. In 1996, two 149 years before the coxibs were approved by the USA FDA, work by Gimbrone and 150 colleagues indicated that under static conditions and with the application of 151 turbulent flow, cultured endothelial cells expressed COX-1, whereas when 152 subject to laminar flow, COX-2 expression was strongly induced and therefore 153 became an important source of enzymatic activity producing precursor for 154 transformation into PGI2 [12] . This finding is significant for being one of the 155 early observations to draw our attention to the impact of shear forces on gene 156 expression and function. Perhaps more importantly, it highlighted the 157 importance of screening drug actions in vitro in settings that are more 158 physiological with regard to flows and forces. The coxibs may compromise 159 endothelial PGI2 production, particularly in regions of high wall shear stress, 160 which are also known to be sites of higher likelihood for rupture of 161 atherosclerotic lesions [13] recent investigations suggest that the maximum response rather than sensitivity 210 is increased [25] . These observations highlight airway stiffness, including 211 airway smooth muscle stiffness, as potential targets for asthma therapy [26, 27] . 212
Force and stiffness development in airway smooth muscle appear to be 213 regulated through separate signal pathways [28, 29] . A recent study showed 214 that fibroblast growth factor-2 (FGF-2) reduces the TGF-β-stimulated increase in 215 stiffness of cultured airway smooth muscle cells [30] showing that repeated challenges with a bronchoconstricting agent, 271 methacholine, induce two major remodeling events; goblet cell hyperplasia and 272 forces are applied to tissue, these forces are transferred from the ECM to the cell, 309
propagating from the outside into the cell ('outside-in'). However, the cell also 310 generates forces within itself, affecting its overall deformability and stiffness. 311
These 'inside-out' forces are also often referred to as the cellular traction force. 312
The forces applied to the cell and the traction forces generated by the cell are Mechanical ventilation was established as a treatment soon after ARDS was first 360 described [60] . Subsequently ventilation volume guidelines were refined in 361 response to the finding that low levels of ventilator-imposed stretch are life-362 saving, whereas higher tidal volumes associated with greater stretch exacerbate 363 lung injury [61] . In common with other causes of ARDS, increased plasma 364 leakage via the compromised microvascular endothelial cell (EC) barrier is the 365 major pathological outcome with ventilator-associated lung injury (VALI). 366
Increased plasma leak is largely attributable to the impact of the large amplitude 367 stretch on EC intercellular forces, signaling pathways, cytoskeletal components, 368 and cell-cell and cell-substrate adhesions [62, 63] . Stretch-induced injury may 369 be elicited mechanically or be secondary to inflammatory processes and/or 370 mediators acting on the EC cytoskeleton.
Regardless, targeting 371 mechanotransduction pathways within the EC has emerged as a dominant 372 therapeutic strategy in ARDS [64, 65] . Key amongst these targets are myosin 373 light chain kinase, small GTPase RhoA, sphingosine-1-phosphate, Rho-specific 374 guanosine nucleotide exchange factor, and protein kinases, amongst others [62, 375 65] . In this connection, Grigoryev et al. examined EC specific gene-expression in 376 human pulmonary microvascular endothelial cells exposed to high levels of 377 cyclic mechanical stretch [66] . They identified several gene variants that confer 378 risk for VALI, including nicotinamide phosphoribosyltransferase (NAMPT) [67] 379 and growth arrest DNA damage inducible alpha (GADD45a) [68] , each of which 380 is currently being pursued as a novel therapeutic target. Taken together, these 381 studies highlight the importance of using cell mechanics to probe gene-382 environmental interactions for drug discovery. conditions, due to their size and the potential to disintegrate. Traction force 552 measurements in spheroids have also been attempted using large aspect ratio 553 micro-pillars [98] . Nonetheless, high-throughput systems based on micro-pillar 554 or cantilever principles have been extremely difficult to construct. Instead, the 555 current state-of-the-art in 3D traction force microscopy is to culture a population 556 of cells in a 3D collagen gel matrix embedded with fluorescent beads. The forces 557 generated by the cells create a pre-stress condition on the gel. Following the 558 experiment, the cell cytoskeleton is destroyed using drugs causing the cell to 559 detach from the gel matrix, releasing the overall pre-stress on the gel, which is 560 tracked by measuring the fluorescent bead displacements [99] . However, 561 challenges remain in relating the overall pre-stress on the gel to the traction 562 force contributions of individual cells. Computational techniques, such as finite 563 element (FE) analysis, have been used to predict the individual cell traction force 564 using information gathered from the overall displacement of beads within the gel 565
[100]. 2D traction force microscopy offers significant potential for high 566 throughput drug screening, but further development is needed for 3D screening 567 with significant throughput. The lung slice may be subjected to traction force 568 microscopy through similar approaches to those used in cell monolayer 569 experiments and has the advantage of maintaining spatial geometry and cell 570 heterogeneity [101] . Particle tracking microrheology may offer an approach to 571 these challenges [102] . 572 573
Concluding Remarks 574 575
The emergence of methodologies to culture cells in microenvironments that 576 better reflect the mechanical, soluble and insoluble (ECM) environment of the 577 diseased tissue bearing the drug target creates an impetus to use such models for 578 drug screening. Efforts to increase the throughput of such methodologies, 579 whilst maintaining cells in a 3D setting with appropriate mechanical loading 580 characteristics need to be complemented by improvements in the patterns of 581 drug and mediator exposure that are also aligned to the patterns prevailing at 582 the drug target in the diseased tissue. A focus on these 583 pharmacodynamic/pharmacokinetic relationships using human cell-derived 3D 584 organoids appears likely to improve their predictive value for target 585 identification and drug screening (see Outstanding questions). We have not 586 covered exciting developments in what might be regarded as mechano-587 pharmaceutics, in which nanotechnology is being applied to pharmaceutical 588 formulation to exploit mechanical forces that cause localized or selective 589 liberation of drugs from their nanoparticle delivery systems [103] . 590
Our view is that there is a need for a sub-discipline of 591 mechanopharmacology, which will serve as a focus for activities that are highly 592 interdisciplinary. The closest term to our proposal is biomechanopharmacology 593 [7] , but this descriptor has not achieved widespread acceptance, perhaps 594 because it is not aligned with similar terms, including mechanomedicine, 595
mechanotherapy [104], mechanotherapeutics [103] and mechanobiology. 596
Mechanopharmacology has been used previously to describe the study of the 597 mechanics of individual proteins [6, 105] ; our proposed usage covers a wider 598 conceptual field. The discussion of best-practice in models, scope of studies, 599 state-of-the-art, and the development of a repository for accepted principles 600 needs to be concentrated rather than distributed amongst a large number of 601 diverse professional/learned societies, as is presently the case. The drive to 602 establish this inter-discipline derives from the desire to improve the relevance of 603 target discovery and screening models to tissues in situ and to human disease, 604 with the ultimate hope of better prediction of efficacy in the clinic. Table 1 
